Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Menter

Showing results (101-110 of 117) with videos related to

Pageof 12
Sort By:
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|October 5, 2015
Patient-relevant needs and treatment goals in nail psoriasisC Blome, A Costanzo, E Dauden, et al.
The British Journal of Dermatology|November 10, 2019
Defining drug-free remission of skin disease in patients with plaque psoriasisA W Armstrong, A Blauvelt, J J Crowley, et al.
Cutis|November 1, 1988
Mometasone furoate ointment and cream 0.1 percent in treatment of psoriasis: comparison with ointment and cream formulations of fluocinolone acetonide 0.025 percent and triamcinolone acetonide 0.1 percentR S Medansky, R Bressinck, G W Cole, et al.
The British Journal of Dermatology|April 8, 2021
The risk of malignancy in patients with secukinumab-treated psoriasis, psoriatic arthritis and ankylosing spondylitis: analysis of clinical trial and postmarketing surveillance data with up to five years of follow-upM Lebwohl, A Deodhar, C E M Griffiths, et al.
The British Journal of Dermatology|January 17, 2007
A classification of psoriasis vulgaris according to phenotypeC E M Griffiths, E Christophers, J N W N Barker, et al.
The British Journal of Dermatology|March 17, 2020
Ustekinumab for the treatment of moderate-to-severe plaque psoriasis in paediatric patients (≥ 6 to < 12 years of age): efficacy, safety, pharmacokinetic and biomarker results from the open-label CADMUS Jr studyS Philipp, A Menter, A F Nikkels, et al.
The British Journal of Dermatology|February 9, 2019
Efficacy and safety of mirikizumab (LY3074828) in the treatment of moderate-to-severe plaque psoriasis: results from a randomized phase II studyK Reich, P Rich, C Maari, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|March 31, 2016
Drug survival of biologic therapy in a large, disease-based registry of patients with psoriasis: results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR)A Menter, K A Papp, M Gooderham, et al.
The British Journal of Dermatology|July 8, 2015
Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trialsK A Papp, M A Menter, M Abe, et al.
The British Journal of Dermatology|September 12, 2015
CARD14 alterations in Tunisian patients with psoriasis and further characterization in European cohortsM Ammar, C T Jordan, L Cao, et al.
Pageof 12

Showing results (101-110 of 117) with videos related to

Sort By:
Pageof 12
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|October 5, 2015
Patient-relevant needs and treatment goals in nail psoriasisC Blome, A Costanzo, E Dauden, et al.
The British Journal of Dermatology|November 10, 2019
Defining drug-free remission of skin disease in patients with plaque psoriasisA W Armstrong, A Blauvelt, J J Crowley, et al.
Cutis|November 1, 1988
Mometasone furoate ointment and cream 0.1 percent in treatment of psoriasis: comparison with ointment and cream formulations of fluocinolone acetonide 0.025 percent and triamcinolone acetonide 0.1 percentR S Medansky, R Bressinck, G W Cole, et al.
The British Journal of Dermatology|April 8, 2021
The risk of malignancy in patients with secukinumab-treated psoriasis, psoriatic arthritis and ankylosing spondylitis: analysis of clinical trial and postmarketing surveillance data with up to five years of follow-upM Lebwohl, A Deodhar, C E M Griffiths, et al.
The British Journal of Dermatology|January 17, 2007
A classification of psoriasis vulgaris according to phenotypeC E M Griffiths, E Christophers, J N W N Barker, et al.
The British Journal of Dermatology|March 17, 2020
Ustekinumab for the treatment of moderate-to-severe plaque psoriasis in paediatric patients (≥ 6 to < 12 years of age): efficacy, safety, pharmacokinetic and biomarker results from the open-label CADMUS Jr studyS Philipp, A Menter, A F Nikkels, et al.
The British Journal of Dermatology|February 9, 2019
Efficacy and safety of mirikizumab (LY3074828) in the treatment of moderate-to-severe plaque psoriasis: results from a randomized phase II studyK Reich, P Rich, C Maari, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|March 31, 2016
Drug survival of biologic therapy in a large, disease-based registry of patients with psoriasis: results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR)A Menter, K A Papp, M Gooderham, et al.
The British Journal of Dermatology|July 8, 2015
Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trialsK A Papp, M A Menter, M Abe, et al.
The British Journal of Dermatology|September 12, 2015
CARD14 alterations in Tunisian patients with psoriasis and further characterization in European cohortsM Ammar, C T Jordan, L Cao, et al.
Pageof 12